This Study Tests the New Medicine BI 754111 Alone or in Combination With Another New Substance BI 754091 in Patients With Advanced Cancer. The Study Tests Different Doses to Find the Best Dose for Continuous Treatment.

Titre officiel

An Open Label, Phase I Dose-finding Study of BI 754111 in Combination With BI 754091 in Patients With Advanced Solid Cancers Followed by Expansion Cohorts at the Selected Dose of the Combination in Patients With Non-small Cell Lung Cancer and Other Solid Tumours

Sommaire:

Cette étude évalue le nouveau médicament BI 754111 en monothérapie ou en association avec le médicament BI 754091 chez les patients atteints d’un cancer à un stade avancé. L’étude évalue différentes doses afin de trouver la dose optimale pour un traitement continu.

Description de l'essai

Primary Outcome:

  • Part I - Maximum-tolerated dose (MTD) of the BI 754111 plus BI 754091 combination
  • Part I - Number of patients experiencing Dose-limiting toxicity (DLTs) during the combination Maximum-tolerated dose (MTD) evaluation period (first cycle of BI 754111 plus BI 754091 combination therapy) in patients with solid tumours
  • Part II - Objective response (OR) - confirmed complete response (CR) and partial response (PR) according to Response Evaluation Criteria in Solid Tumours (RECIST) Version 1.1 as assessed by the Investigator during the entire treatment
Secondary Outcome:
  • Part I - Cmax: maximum measured concentration of BI 754111/ BI 754091 in plasma
  • Part I - AUC 0-504: Area under the Concentration Time Curve (AUC 0-504) of BI 754111/ BI 754091 in plasma over the time interval
  • Part I - Number of patients experiencing Dose-limiting toxicity (DLTs) from start of treatment until end of treatment (in all cycles)
  • Part I - Objective response (OR) for patients with solid tumours: confirmed complete response (CR) and partial response (PR) according to RECIST Version 1.1 as assessed by the Investigator during the entire treatment period
  • Part II - Duration of response is the duration from the date of first documented PR or CR according to RECIST Version 1.1 as assessed by the Investigator to the date of Progression of disease [PD] or death
  • Part II - Disease control (CR, PR, or SD according to RECIST Version 1.1) as assessed by the Investigator
  • Part II - Progression-free survival (PFS) is the duration from the date of first treatment to the date of PD or death
  • Part II - PK parameters: Cmax, and AUC 0-504, will be calculated for BI 754111 and BI 754091 after single and multiple doses of the BI 754111 plus BI 754091 combination treatment
  • Part II - Number of patients experiencing DLTs from start of treatment until end of treatment

Voir cet essai sur ClinicalTrials.gov

Intéressé(e) par cet essai?

Imprimez cette page et apportez-la chez votre médecin pour discuter de votre admissibilité à cet essai et des options de traitement. Seul votre médecin peut vous recommander pour un essai clinique.

Ressources

Société canadienne du cancer

Ces ressources sont fournies en partenariat avec Société canadienne du cancer